Application of eleutheroside E in preparation of rheumatoid arthritis treating medicine

An echinocoside and rheumatoid technology, applied in the field of medicine, can solve the problems of unreported research and low activity, and achieve the effects of reversing joint pathological damage, reducing antibody levels, and having a clear industrialization prospect.

Active Publication Date: 2014-05-28
THE SECOND HOSPITAL AFFILIATED TO SUZHOU UNIV +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] As a known monomer compound, eleutheroside E is not very active in research despite its exact molecular formula and structural formula. At present, there are very few reports on the pharmacological effects of eleutheroside E. It is mainly used to lower blood sugar, resist central fatigue, improve myocardial mechanical changes caused by pi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eleutheroside E in preparation of rheumatoid arthritis treating medicine
  • Application of eleutheroside E in preparation of rheumatoid arthritis treating medicine
  • Application of eleutheroside E in preparation of rheumatoid arthritis treating medicine

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0044] Preparation of serum: After taking blood from mice in each group through orbital extraction, centrifuge at 4000r / min for 20min at 4°C overnight, and carefully take the supernatant and place it in a 0.5ml centrifuge tube. The prepared serum was stored in a refrigerator at -20°C to determine the level of anti-collagen type II antibodies in the serum.

[0045] 3. Joint score

[0046] Mouse joint inflammation and scoring were as follows: 0: no significant change; 1: obvious swelling and redness of one toe; 2: mild swelling and erythema of limbs or swelling of two toes; 3: three toes appeared Obvious swelling and erythema of the limbs; 4: Swelling and redness of the entire joint, and even joint stiffness.

[0047] 4. Histopathological observation:

[0048] The hind paws (hind paws and joints) of mice were fixed with 10% formaldehyde, then soaked in 10% EDTA solution for two days for decalcification, embedded in paraffin, tissue sections of 5 μm, and then stained with HE. ...

Embodiment 1

[0058] Example 1 Effect of eleutheroside E on mouse joints, body weight and foot volume

[0059] Experimental mice were treated with eleutheroside E by intragastric administration, and the joint score, body weight and hind paw thickness were counted. The results showed that the hind paws of the mice in the model group had obvious redness and swelling and joint stiffness, while eleutheroside E and TG The lesion degree of the mice in the treatment group was significantly reduced ( Figure 1A ). Compared with the model group, the joint scores and weight loss of mice in the 15mg / kg TG treatment group, 30mg / kg and 60mg / kg eleutheroside E treatment groups were significantly reduced (P0.05), see Figure 1B and 1C . The thickness of the hind paw of mice in the 30mg / kg and 60mg / kg eleutheroside E treatment groups decreased significantly from 42 days to 56 days after the first injection, but the 15mg / kg eleutheroside E treatment group did not show significant improvement effect, see ...

Embodiment 2

[0060] Example 2 The effect of eleutheroside E treatment on joint bone destruction

[0061] Mammography X-ray plain films and micro-CT examinations were carried out on the hind paws of the mice. The molybdenum-palladium X-ray films showed that the hind paw joints of the mice in the model group were obviously destroyed, displaced and irregular bone hyperplasia, while eleutheroside E ( 30mg / kg, 60mg / kg) and TG (15mg / kg) treatment groups, the degree of bone destruction in mice was significantly reduced, see Figure 2A . Correspondingly, the scores of the degree of bone destruction of the mice in the eleutheroside E (30mg / kg, 60mg / kg) and TG (15mg / kg) treatment groups were also significantly reduced (P Figure 2C . Compared with the model group, the mice in the 15mg / kg eleutheroside E treatment group did not show significant improvement (P>0.05). Using micro-CT to scan the hind paws of the mice, it was also found that the mice in the model group had obvious joint destruction, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel application of eleutheroside E, in particular to an application of the eleutheroside E in preparation of a rheumatoid arthritis treatment medicine and medicine composition for treating the rheumatoid arthritis. The medicine composition for treating the rheumatoid arthritis can be prepared into tablets, capsules, a dissolved medicine, drops, granules, an ointment or an injection through the eleutheroside E with purity higher than 98% (mass percentage) added with universal auxiliary medical components. Pharmacology experiment results show that the eleutheroside E can remarkably improve the joint swelling condition of the rheumatoid arthritis, reduce the arthritis index, reverse pathologic change of arthritis, has no critical defects of clinically common medicines, and has the function of the rheumatoid arthritis resistance with high efficiency and low toxicity. Therefore, the eleutheroside E can be used for preparing the medicine for treating the rheumatoid arthritis. The invention provides a novel medicine source for treating the rheumatoid arthritis.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to the application of eleutheroside E in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is a multisystemic inflammatory autoimmune disease mainly involving peripheral joints with unknown etiology. Rheumatoid arthritis is the most common inflammatory joint disease clinically, which seriously affects the functional status, quality of life and life expectancy of patients. Because of its chronic characteristics, related complications and long-term dysfunction, it has a huge impact on society and economy . The current treatment of rheumatoid arthritis is mainly based on drug therapy (commonly used drugs are non-steroidal anti-inflammatory drugs, newly listed biological agents such as TNF-a inhibitors), but none of the drugs can really completely control the development of the disease, and There are serious side eff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P19/02A61P29/00
Inventor 何春燕闫兆威朱雪明陈晓辉
Owner THE SECOND HOSPITAL AFFILIATED TO SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap